Related Experiment Video

Updated: Jun 21, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Expression of the Bcl-2 protein BAD promotes prostate cancer growth

Adrienne J Smith1, Yelena Karpova, Ralph D'Agostino

  • 1Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Plos One
|July 14, 2009
PubMed

Insights

Prostate cancer cells increase BAD protein levels for proliferation, while phosphorylation controls apoptosis. Targeting BAD-phosphorylating kinases may offer new prostate cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • BAD is a pro-apoptotic protein of the Bcl-2 family.
  • BAD integrates anti-apoptotic signaling pathways (EGFR, GPCRs, PI3K) in prostate cancer.
  • Elevated BAD levels are observed in prostate carcinomas, seemingly contradictory to its pro-apoptotic function.

Purpose of the Study:

  • To investigate the dual role of BAD in prostate cancer proliferation and apoptosis.
  • To explore the implications of BAD expression levels and phosphorylation status in prostate cancer progression.
  • To identify potential therapeutic targets and predictive biomarkers related to BAD in prostate cancer.

Main Methods:

  • Analysis of BAD's effect on prostate cancer xenografts.
  • Tissue culture experiments to assess the impact of BAD expression on cell proliferation.
  • Investigating the role of BAD phosphorylation in apoptosis regulation.

Main Results:

  • Increased BAD expression enhances prostate cancer xenograft growth.
  • Increased BAD expression stimulates proliferation of prostate cancer cells in tissue culture.
  • BAD dephosphorylation increases sensitivity to apoptosis, while phosphorylation promotes proliferation.

Conclusions:

  • Prostate cancer cells exhibit an "addiction" to increased levels of phosphorylated BAD for proliferation and survival.
  • Kinases that phosphorylate BAD are potential therapeutic targets for prostate cancer.
  • Monitoring BAD phosphorylation may serve as a predictive biomarker for treatment response.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts09:43

Isolation, Culture, and Characterization of Prostate Cancer-Associated Fibroblasts

Published on: August 1, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.